Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al

Arthritis & RheumatologyVolume 71, Issue 6 p. 1023-1024 Letters Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al Aryeh M. Abeles MD, Aryeh M. Abeles MD University of Connecticut Health Center, Farmington, CTSearch for more papers by this authorMichael H. Pillinger MD, Michael H. Pillinger MD New York University School of Medicine, New York, NYSearch for more papers by this author Aryeh M. Abeles MD, Aryeh M. Abeles MD University of Connecticut Health Center, Farmington, CTSearch for more papers by this authorMichael H. Pillinger MD, Michael H. Pillinger MD New York University School of Medicine, New York, NYSearch for more papers by this author First published: 18 January 2019 https://doi.org/10.1002/art.40838Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume71, Issue6June 2019Pages 1023-1024 RelatedInformation